Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

This study is testing a new drug called AZD4512, which targets the CD22 protein found on certain leukemia cells, either alone or combined with other cancer treatments. It is for patients with B-cell acute lymphoblastic leukemia (B-ALL) — a blood cancer — that has come back or stopped responding to treatment. **You may be eligible if (Module 1 — adults/teens):** - You are 16 or older (18 or older in the US) - You have CD22-positive B-ALL that is relapsed or refractory - You have received at least 2 prior treatments that failed, or 1 prior treatment with no remaining standard options - Your overall health is adequate (ECOG 0–2) **You may be eligible if (Module 2 — pediatric):** - You are 12 or older - You have relapsed/refractory Ph-negative B-ALL **You may NOT be eligible if:** - Your cancer does not express CD22 - Your leukemia blast count is very high (above 10,000/µL) unless reduced before starting - You have significant organ problems or other serious health conditions Talk to your doctor to see if this trial is right for you.